Updated on June 4, 2026 · Published by PatSnap Open Intelligence Team
You’ve narrowed five analogs to three leads. Before you commit synthesis time and in vivo slots, you need to know: Will this compound absorb orally? Cross the blood-brain barrier? Trigger hERG liability? ADMET prediction uses computational models to estimate how a compound behaves in the body — before you synthesize it.
Traditional ADMET profiling takes weeks and burns milligrams. Computational prediction gives you a first-pass filter in seconds — but only if you understand what the numbers mean and which risks the models can’t see. This guide explains what ADMET parameters mean, how prediction works, and how medicinal chemists run it inside AI workflows.
What Is ADMET Prediction?
ADMET prediction is the computational estimation of a compound’s
Absorption, Distribution, Metabolism, Excretion, and Toxicity properties based on chemical structure. Instead of synthesizing a molecule and running in vitro assays, you input a SMILES string and receive predicted values for parameters like oral bioavailability, clearance, and cytochrome P450 (CYP) inhibition. These predictions help medicinal chemists prioritize which analogs deserve experimental validation.Modern ADMET models use machine learning trained on millions of experimental measurements from databases like
ChEMBL and
PubChem. Tools like
PatSnap Chemical Molecular MCP — built by
PatSnap, the patent intelligence platform — implement ADMET-AI (a Chemprop ensemble model) inside AI environments like Claude, letting you predict ADMET properties conversationally during structure searches or scaffold optimization. The goal isn’t to replace wet-lab assays — it’s to fail faster on compounds with dealbreaker liabilities before you invest synthesis resources.Each letter in ADMET maps to a pharmacokinetic or safety decision.
Absorption predicts oral uptake (human intestinal absorption, Caco-2 permeability).
Distribution estimates tissue penetration (blood-brain barrier permeability, volume of distribution).
Metabolism flags CYP interactions (which isoforms metabolize your compound, which it inhibits).
Excretion predicts clearance rates (hepatocyte clearance, half-life).
Toxicity screens for red flags (AMES mutagenicity, hERG cardiotoxicity, drug-induced liver injury).
How ADMET Prediction Works
ADMET prediction translates your compound’s structure into numeric fingerprints, then feeds those fingerprints to machine learning models trained on experimental data. Here’s the typical workflow:
- Input structure. You provide a SMILES string, InChI, or structure file. The tool converts this to molecular descriptors — numerical representations of atom types, bond patterns, and 3D properties.
- Model inference. Separate models predict each ADMET endpoint. For example, one graph neural network predicts Caco-2 permeability; another predicts CYP2D6 substrate likelihood. Ensemble models (like ADMET-AI) average predictions from multiple architectures to improve accuracy.
- Output scores. You receive numeric predictions — percentages (e.g., 94.5% oral bioavailability), classifications (e.g., “CYP2C9 substrate: yes”), or continuous values (e.g., clearance 22.0 µL/min/10⁶ cells). Many tools also flag Lipinski Rule of Five (Ro5) violations.
- Interpret in context. Compare predictions to reference ranges. For example, Caco-2 permeability above -5.0 log cm/s suggests good passive absorption; hERG inhibition above 10 µM IC₅₀ (or low predicted probability) reduces cardiac risk.
For a known drug like ibuprofen, predicted values align tightly with experimental data — demonstrating model validity. For novel analogs, you use these predictions to rank compounds before committing to synthesis.
Example output for ibuprofen (SMILES CC(C)CC1=CC=C(C=C1)C(C)C(=O)O): Oral bioavailability 94.5% (matches clinical 87–100%), primary CYP2C9 substrate 65.3% (clinically confirmed), hepatocyte clearance 22.0 µL/min/10⁶ cells (implies 1.5–3 h half-life; clinical ~2 h), AMES mutagenicity 0.58% (very low), hERG cardiotoxicity 0.84% (very low).
Why It Matters for Medicinal Chemists
ADMET prediction reshapes early-stage decision-making. In hit-to-lead and lead optimization, you’re balancing potency, selectivity, and drug-likeness across dozens of analogs. Synthesis capacity is finite; in vivo slots fill fast. Computational ADMET lets you triage before the bottleneck: deprioritize compounds with predicted poor absorption, flag CYP inhibitors that risk drug-drug interactions, and identify CNS penetration mismatches (too much BBB permeability for a peripheral target, too little for a CNS indication).The typical use case: You’ve designed five analogs around a scaffold. Before synthesis, you run ADMET predictions. Two compounds show hERG liability above your threshold. One has hepatocyte clearance suggesting a sub-1-hour half-life. You synthesize the remaining two, saving three weeks and three milligrams of reference standard. When one of those two advances to in vivo PK, the experimental Cₘₐₓ and AUC align with predicted absorption — validating your decision to prioritize it.The MCP brings this workflow into AI assistants like Claude or Cursor. You can structure-search a scaffold, extract analogs from competitor patents, then predict ADMET properties — all in one conversational thread. You can structure-search a scaffold, extract analogs from competitor patents, then predict ADMET properties for each hit — all in one conversational thread. Instead of exporting SMILES to a separate tool, you ask “predict ADMET for these five structures” and receive ranked results with physicochemical context (molecular weight, logP, Lipinski compliance). When a compound shows borderline BBB penetration, you immediately search for brain-penetrant analogs in the same patent family — accelerating scaffold hopping without switching tools.
What ADMET Prediction Does Not Do
ADMET models predict
structure-based endpoints, not
mechanism-based toxicity. For example, ibuprofen’s predictions show low AMES mutagenicity and low hERG liability — both accurate. But the model cannot predict gastrointestinal ulceration, renal toxicity, or cardiovascular risk from COX-1 inhibition, because those effects depend on pharmacodynamic mechanisms (enzyme inhibition, receptor binding) that cheminformatic models don’t capture. You still need target-based assays and in vivo studies to assess on-target and off-target liabilities.ADMET prediction is a
prioritization filter, not a regulatory submission package. Use it to fail fast on dealbreakers and rank candidates for experimental validation — but never skip wet-lab confirmation for compounds advancing to IND-enabling studies.
Try It Yourself
Two paths to start predicting ADMET properties today:
- Browser (no install): Open PatSnap Eureka, paste a SMILES string, and ask “predict ADMET properties.” Results appear in seconds with physicochemical context.
- AI workflow (Claude, Cursor, Continue.dev): Sign up for a free API key at open.patsnap.com, then add the Chemical Molecular MCP from the marketplace. You get 10,000 free credits, no credit card required. Let your AI assistant handle configuration, then ask “predict ADMET for this SMILES” to verify the connection.
Both paths query the same ADMET-AI Chemprop ensemble model and compound database. Eureka is fastest for one-off predictions; the MCP integrates ADMET into structure searches and patent workflows.
What does ADMET stand for in drug discovery?
ADMET stands for
Absorption, Distribution, Metabolism, Excretion, and Toxicity — the five pharmacokinetic and safety categories that determine whether a compound becomes a drug. Absorption covers oral uptake and permeability. Distribution predicts tissue penetration. Metabolism flags cytochrome P450 interactions. Excretion estimates clearance and half-life. Toxicity screens for mutagenicity, cardiotoxicity, and liver injury. Predicting these properties computationally helps chemists prioritize which analogs to synthesize before running expensive in vitro and in vivo assays. You can test predictions immediately using
PatSnap Eureka — paste a SMILES string and receive results in seconds.
How accurate are ADMET prediction models?
Accuracy varies by endpoint and training data size. For well-studied parameters like oral bioavailability and CYP substrate classification, modern graph neural networks achieve 70–85% accuracy against experimental benchmarks from resources like
ChEMBL. For example, ADMET-AI correctly predicted ibuprofen’s 94.5% bioavailability (clinical range 87–100%) and CYP2C9 metabolism. However, mechanism-based toxicities (e.g., COX inhibition, immune-mediated reactions) fall outside model scope because they depend on target interactions, not chemical structure alone. Use predictions to rank candidates and filter obvious failures — always confirm with wet-lab assays before advancing to preclinical development. Start validating predictions for your compounds at
open.patsnap.com with 10,000 free credits.
When should I run ADMET predictions during drug discovery?
Run ADMET predictions during
hit-to-lead triage and
lead optimization — after you’ve identified a chemical series with acceptable potency, before you commit synthesis resources to dozens of analogs. Early predictions help you eliminate compounds with dealbreaker liabilities (poor absorption, hERG risk, reactive metabolites) and prioritize structures likely to pass in vitro profiling. Many teams also use ADMET prediction during
scaffold hopping to ensure new cores retain drug-like properties. Running predictions too early (e.g., during HTS hit validation) wastes time on compounds you’ll deprioritize for potency; running them too late (post-synthesis) misses the efficiency gain. Integrate predictions into your workflow by adding the Chemical Molecular MCP from the
marketplace — combine ADMET with structure searches and analog ranking in one session.
How do I start running ADMET predictions in my workflow?
For quick one-off predictions, open
PatSnap Eureka in your browser, paste a SMILES string, and ask “predict ADMET.” No installation required. For integrated workflows — combining ADMET with structure searches from
PubChem, patent extractions, or analog ranking — sign up at
open.patsnap.com for a free API key (10,000 credits, no credit card), then install the Chemical Molecular MCP from the
marketplace. Both paths use the same ADMET-AI model and compound database; choose based on whether you need standalone predictions or multi-step cheminformatics workflows.
Ready to Predict Your First Compound’s ADMET Profile?
Start free — 10,000 credits, no credit card, no subscription.→
Get Your API Key — sign up at open.patsnap.com→
Add the MCP to Your AI — find it in the marketplace→
Try in Browser — PatSnap Eureka, no install
Note: Information based on publicly available sources as of 2026. Product features may change. Contact PatSnap.
